In this study, we evaluated the epithelial and stromal cellular expression of CXCR4-CXCL12-CXCR7 in tumors from advanced ovarian cancer patients enrolled in the MITO16A/MaNGO-OV2 trial [25]. This evidence concerns the gene CXCL12 and ovarian carcinoma.